Liposome as nanocarrier: Site targeted delivery in lung cancer

Ullah, Najeeb; Noreen, Saba C Saba; Tehreem, Kanza; Zaman, Aqal; Ahmad, Zara Zara; Balouch, Humaira; Samad, Noreen

doi:10.12980/apjtd.7.2017d6-182

Cited by 2 publications

(2 citation statements)

References 101 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, because of high-dose administration of Ketotifen (in mg level) the liposomal formulation would not be able to carry effective and required amounts of Ketotifen to the deep parts of the lung. Furthermore, particle aggregation is the main drawback of the solid state of lipid-based carriers such as liposomes [18,19]. Therefore, the primary aim of this study was to prepare a carrier-free Ketotifen DPI formulation for pulmonary delivery via an industrial and easily scaled-up approach.…”

Section: Introductionmentioning

confidence: 99%

Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery

et al. 2019

View full text Add to dashboard Cite

Background Pulmonary drug delivery route is gaining much attention because it enables to target the active ingredients directly to lung both for local and systemic treatments, which maximize the therapeutic effect and minimize unwanted systemic toxicity. Dry powder inhaler (DPI) systems for asthma therapy have shown several merits to the other pulmonary delivery systems such as nebulizers and metered dose inhalers. Purpose The present study aims to develop and optimize a DPI formulation for Ketotifen fumarate through spray drying technique. Methods Particles size and morphology, crystallinity, and drug-excipient interaction of fabricated DPI formulations were evaluated by scanning electron microscopy, X-ray diffraction (XRD), differential scanning calorimetry (DSC), and Fourier Transform Infrared Spectroscopy methods, respectively. The aerosolization indexes and aerodynamic properties of dry powders were determined by next generation impactor. The powder flowability was assessed by measuring the Hausner ratio and compressibility index. Results Among solvent systems, ethanol-water mixture produced the most desirable powder property for inhalation after spray drying. Although co-spray dried formulations with ammonium bicarbonate resulted in the porous structure, it was not beneficial for DPI formulations due to the interaction with Ketotifen. DSC and XRD experiments proved the amorphous structure of prepared powders, which were stable for 12 months. Conclusion The results of this study demonstrate the potential of Ketotifen DPI formulation and pave a way to use it easily in an industrial scale.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Nano-liposomes loaded with ligands or antibodies have been reviewed for their performance in the therapy of lung cancers. Najeeb Ullah et al [ 34 ] provided in-depth insight into the site-directed application of nano-liposomes to release their encapsulated drugs to tumor areas. On the other hand, the appropriate design of the drug-carrier complex is key for successful drug delivery.…”

Section: Introductionmentioning

confidence: 99%

Magnetic particle targeting for diagnosis and therapy of lung cancers

Saadat

Manshadi

Mohammadi

et al. 2020

Journal of Controlled Release

View full text Add to dashboard Cite

Over the past decade, the growing interest in targeted lung cancer therapy has guided researchers toward the cutting edge of controlled drug delivery, particularly magnetic particle targeting. Targeting of tissues by magnetic particles has tackled several limitations of traditional drug delivery methods for both cancer detection (e.g., using magnetic resonance imaging) and therapy. Delivery of magnetic particles offers the key advantage of high efficiency in the local deposition of drugs in the target tissue with the least harmful effect on other healthy tissues. This review first overviews clinical aspects of lung morphology and pathogenesis as well as clinical features of lung cancer. It is followed by reviewing the advances in using magnetic particles for diagnosis and therapy of lung cancers: (i) a combination of magnetic particle targeting with MRI imaging for diagnosis and screening of lung cancers, (ii) magnetic drug targeting (MDT) through either intravenous injection and pulmonary delivery for lung cancer therapy, and (iii) computational simulations that models new and effective approaches for magnetic particle drug delivery to the lung, all supporting improved lung cancer treatment. The review further discusses future opportunities to improve the clinical performance of MDT for diagnosis and treatment of lung cancer and highlights clinical therapy application of the MDT as a new horizon to cure with minimal side effects a wide variety of lung diseases and possibly other acute respiratory syndromes (COVID-19, MERS, and SARS).

show abstract

Liposome as nanocarrier: Site targeted delivery in lung cancer

Cited by 2 publications

References 101 publications

Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery

Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery

Magnetic particle targeting for diagnosis and therapy of lung cancers

Contact Info

Product

Resources

About